Overview

Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency

Status:
Unknown status
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
Treatment of neutropenia of G6PC3 and Glycogenosis type 1b patients with empagliflozin
Phase:
Phase 2
Details
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Treatments:
Empagliflozin